FSCN1 and osteosarcoma: Recent studies on osteosarcoma involving the LCP1 gene (also known as actin-bundling protein L-plastin or LPL), have shown that the aberrant expression of LCP1 gene activates the JAK2/STAT3 signaling pathway, linking IL-6, IL-6R, and LCP1 in the context of tumor progression47.